Quarterly report · Q1
8086.TEDINET S100OZ7P
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥127.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥494.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥118.0bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥3.0bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥5.5bn | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥7.3bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥27.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.2bn | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥9.0bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥5.3bn | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.3bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.3bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥5.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥3.5bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥947.6bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥930.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥874.8bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥730.3bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥730.5bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥217.3bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥199.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥185.9bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥84.7bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥95.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥32.35 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.5 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥20.24 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥28.66 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥77.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 21.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.8% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-06-30 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥154m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥855m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-06-30 | ¥211m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥9.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥9.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥7.1bn |
| jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥99.3bn |
| jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥97.7bn |
| jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥1.6bn |
| jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥8.5bn |
| jpcrp040300-q1r_E02688-000Medicine Relatedreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥23.2bn |
| jpcrp040300-q1r_E02688-000Medicine Relatedreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥17.9bn |
| jpcrp040300-q1r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥5.3bn |
| jpcrp040300-q1r_E02688-000Medicine Relatedreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥407m |
| jpcrp040300-q1r_E02688-000Pharma Packagingreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥13.7bn |
| jpcrp040300-q1r_E02688-000Pharma Packagingreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥12.2bn |
| jpcrp040300-q1r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q1r_E02688-000Pharma Packagingreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.0bn |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥136.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥127.7bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥8.4bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥137.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥127.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥9.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥10.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-06-30 | ¥693m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-06-30 | ¥153m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥540m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-06-30 | ¥145m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥8.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥8.8bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥5.6bn |
| jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥92.2bn |
| jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥90.6bn |
| jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥1.5bn |
| jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥9.5bn |
| jpcrp040300-q1r_E02688-000Medicine Relatedreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥21.5bn |
| jpcrp040300-q1r_E02688-000Medicine Relatedreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥16.4bn |
| jpcrp040300-q1r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥5.1bn |
| jpcrp040300-q1r_E02688-000Medicine Relatedreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥587m |
| jpcrp040300-q1r_E02688-000Pharma Packagingreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥12.4bn |
| jpcrp040300-q1r_E02688-000Pharma Packagingreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥10.8bn |
| jpcrp040300-q1r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥1.6bn |
| jpcrp040300-q1r_E02688-000Pharma Packagingreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥844m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥126.1bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥117.8bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥8.2bn |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥10.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-06-30 | ¥126.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-06-30 | ¥118.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥8.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-06-30 | ¥11.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 442
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)ニプロ株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)大阪市北区本庄西３丁目９番３号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding trade notes receivable discounted or transferred by endorsement (text) | CurrentQuarterInstant | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |